Motley Fool Asset Management LLC Seagen Inc. Transaction History

Motley Fool Asset Management LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	BUY	$191.51 - $216.16 $88,669 - $100,082	463 Added 10.7%	4,790 $1.02 Million
Q2 2023 Aug 09, 2023	BUY	$187.64 - $206.25 $811,918 - $892,443	4,327 New	4,327 $832,000
Q4 2022 Feb 09, 2023	SELL	$117.37 - $139.17 $33,567 - $39,802	-286 Reduced 7.87%	3,350 $430,000
Q3 2022 Nov 14, 2022	SELL	$135.27 - $180.11 $9,468 - $12,607	-70 Reduced 1.89%	3,636 $498,000
Q2 2022 Aug 11, 2022	BUY	$108.81 - $179.33 $326 - $537	3 Added 0.08%	3,706 $655,000

Q1 2022 May 04, 2022	BUY	$119.61 - $157.85 $432,629 - $570,943	3,617 Added 4205.81%	3,703 $533,000
Q4 2021 Feb 10, 2022	BUY	$142.57 - $190.86 $12,261 - $16,413	86 New	86 $13,000
Q2 2021 Aug 13, 2021	SELL	$135.08 - $161.1 $5.6 Million - $6.68 Million	-41,467 Closed	0 $0
Q1 2021 May 11, 2021	BUY	$137.51 - $190.8 $5.06 Million - $7.03 Million	36,828 Added 793.88%	41,467 $3.16 Million
Q4 2020 Feb 12, 2021	BUY	$164.63 - $211.93 $763,718 - $983,143	4,639 New	4,639 $812,000

1.26M

23K

55.2K

Ticker SGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,664,992
Description
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...

Get notified when there are updates to the investment portfolio of Motley Fool Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Motley Fool Asset Management LLC with notifications on news.